Trials / Completed
CompletedNCT01686152
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 589 (actual)
- Sponsor
- Teva Pharmaceuticals USA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp. It will also be determined whether the efficacy of each of the two active treatments is superior to that of the Vehicle cream.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod Cream, 3.75% | |
| DRUG | Zyclara® | |
| OTHER | Vehicle of Test Product |
Timeline
- Start date
- 2012-09-01
- Primary completion
- 2013-08-01
- Completion
- 2013-08-01
- First posted
- 2012-09-17
- Last updated
- 2020-11-24
- Results posted
- 2020-10-30
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01686152. Inclusion in this directory is not an endorsement.